<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03174366</url>
  </required_header>
  <id_info>
    <org_study_id>20159178</org_study_id>
    <nct_id>NCT03174366</nct_id>
  </id_info>
  <brief_title>Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy</brief_title>
  <official_title>Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western University of Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Charcot neuroarthropathy (CN) is a debilitating disease primarily affecting poorly controlled
      diabetic patients with peripheral neuropathy. The consequences of CN include ulcerations of
      the foot and ankle, osteomyelitis, and severe musculoskeletal deformity. These consequences
      frequently lead to below-knee amputation of the affected limb.

      Currently treatment options are limited, and no pharmaceutical treatment has been efficacious
      in the medical literature. The purpose of this pilot study is to investigate the potential of
      the medication denosumab for acute stage Charcot neuroarthropathy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 16, 2017</start_date>
  <completion_date type="Actual">March 6, 2019</completion_date>
  <primary_completion_date type="Actual">June 18, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Skin Temperature Difference in Degrees Celsius Between the Affected and Non-affected Limb at 6 Months.</measure>
    <time_frame>6 months</time_frame>
    <description>Change in skin temperature difference in degrees Celsius between the affected and non-affected limb at 6 months.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Charcot Joint of Foot</condition>
  <arm_group>
    <arm_group_label>Intervention Group, receiving medication</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group will be receiving medication (denosumab)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>Subjects will receive medication once following enrollment, and will be monitored for 1 year thereafter.</description>
    <arm_group_label>Intervention Group, receiving medication</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women &gt; 30 years old

          -  Subject is able and willing to comply with study procedures, and is able to give
             signed and dated consent

          -  Subject meets criteria for diagnosis of Diabetes Mellitus Type 1 or 2, active Charcot
             neuroarthropathy, and peripheral neuropathy

          -  Subjects with serum calcium or albumin-adjusted serum calcium â‰¥2.0 mmol/L (8.0mg/dL)

        Exclusion Criteria:

          -  Unable to provide signed and dated consent.

          -  Charcot neuroarthropathy of the ipsilateral lower extremity, diagnosed over 1 month
             prior.

          -  Prior foot or ankle surgery of the ipsilateral lower extremity.

          -  Prior amputation at any level of either lower extremity.

          -  Prior foot or ankle fracture of the ipsilateral lower extremity unrelated to the
             current acute CN episode.

          -  Currently has any of the following:

               1. Infection

               2. Foot ulceration

               3. Hypocalcemia

               4. Creatinine clearance less than 30 mL/min or on dialysis

               5. Pre-existing disturbance of mineral metabolism (e.g., hypoparathyroidism unstable
                  on therapy, thyroid or parathyroid surgery, vitamin D deficiency, malabsorption
                  syndromes, excision of small intestine, history of diseases affecting bone
                  metabolism) that has not been effectively corrected or treated.

          -  Have undergone revascularization procedures of the lower extremities.

          -  Female subjects who are pregnant or planning to breastfeed should not participate in
             this study.

          -  Determined to have poor oral hygiene after dental screening or are at increased risk
             for developing osteonecrosis of the jaw.

          -  History of osteonecrosis of the jaw.

          -  History of tooth extraction or other dental surgery within the prior 6 months.

          -  Invasive dental work planned in the next 2 years.

          -  Have a known hypersensitivity to Prolia.

          -  Known use of a bone active medication within the 6 months prior to enrollment.

          -  Liver disease, defined as AST &gt; 2.0x ULN, ALT &gt; 2.0x ULN, TBL &gt; 1.5x ULN.

          -  Malignancy within the last 5 years (except cervical carcinoma in situ or basal cell
             carcinoma)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Western University of Health Sciences</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2017</study_first_posted>
  <results_first_submitted>October 1, 2019</results_first_submitted>
  <results_first_submitted_qc>October 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 23, 2019</results_first_posted>
  <last_update_submitted>October 22, 2019</last_update_submitted>
  <last_update_submitted_qc>October 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthropathy, Neurogenic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT03174366/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention Group, Receiving Medication</title>
          <description>Subjects in this group will be receiving medication (denosumab)
Denosumab: Subjects will receive medication once following enrollment, and will be monitored for 1 year thereafter.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention Group, Receiving Medication</title>
          <description>Subjects in this group will be receiving medication (denosumab)
Denosumab: Subjects will receive medication once following enrollment, and will be monitored for 1 year thereafter.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="10.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity</title>
              <category_list>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African-American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mixed Hispanic/Native American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</title>
        <description>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group, Receiving Medication</title>
            <description>Subjects in this group will be receiving medication (denosumab)
Denosumab: Subjects will receive medication once following enrollment, and will be monitored for 1 year thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</title>
          <description>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Serious adverse event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No serious adverse events</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Skin Temperature Difference in Degrees Celsius Between the Affected and Non-affected Limb at 6 Months.</title>
        <description>Change in skin temperature difference in degrees Celsius between the affected and non-affected limb at 6 months.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group, Receiving Medication</title>
            <description>Subjects in this group will be receiving medication (denosumab)
Denosumab: Subjects will receive medication once following enrollment, and will be monitored for 1 year thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Skin Temperature Difference in Degrees Celsius Between the Affected and Non-affected Limb at 6 Months.</title>
          <description>Change in skin temperature difference in degrees Celsius between the affected and non-affected limb at 6 months.</description>
          <units>degrees Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.06" spread="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention Group, Receiving Medication</title>
          <description>Subjects in this group will be receiving medication (denosumab)
Denosumab: Subjects will receive medication once following enrollment, and will be monitored for 1 year thereafter.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <description>Cellulitis of the contralateral lower extremity, resolved with oral antibiotics</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle pain, upper extremity</sub_title>
                <description>Injection site pain, resolved after two weeks</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Shofler</name_or_title>
      <organization>Western University of Health Sciences</organization>
      <phone>9097063898</phone>
      <email>dshofler@westernu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

